Encorafenib plus binimetinib in patients with locally advanced, unresectable or metastatic BRAFV600-mutated melanoma: an ongoing multi-centric, multi-national, prospective, longitudinal, non-interventional study - BERING-Melanoma

D Schadendorf; E Richtig; C Loquai; A Forschner; R Gutzmer; S Haferkamp; J Utikal; JC Hassel; F Meier; Dirk Debus; M Fluck; D Goeppner; H Kehrer; R Dummer; R von Moos; J Thompson; L Gengenbacher; O Michielin; C Hoeller

Encorafenib plus binimetinib in patients with locally advanced, unresectable or metastatic BRAFV600-mutated melanoma: an ongoing multi-centric, multi-national, prospective, longitudinal, non-interventional study - BERING-Melanoma

D Schadendorf, E Richtig, C Loquai, A Forschner, R Gutzmer, S Haferkamp, J Utikal, JC Hassel, F Meier, Dirk Debus, M Fluck, D Goeppner, H Kehrer, R Dummer, R von Moos, J Thompson, L Gengenbacher, O Michielin, C Hoeller

Department of Dermatology

Research output: Contribution to journal › Abstract (Journal) › peer-review

Original language	English
Pages (from-to)	236-236
Journal	Oncology Research and Treatment
Volume	45
Issue number	SUPPL 3
Publication status	Published - 2022

Cite this

Schadendorf, D., Richtig, E., Loquai, C., Forschner, A., Gutzmer, R., Haferkamp, S., Utikal, J., Hassel, JC., Meier, F., Debus, D., Fluck, M., Goeppner, D., Kehrer, H., Dummer, R., von Moos, R., Thompson, J., Gengenbacher, L., Michielin, O., & Hoeller, C. (2022). Encorafenib plus binimetinib in patients with locally advanced, unresectable or metastatic BRAFV600-mutated melanoma: an ongoing multi-centric, multi-national, prospective, longitudinal, non-interventional study - BERING-Melanoma. Oncology Research and Treatment, 45(SUPPL 3), 236-236.

@article{bc2cd4734f9b4638a095edd81894d1ec,

title = "Encorafenib plus binimetinib in patients with locally advanced, unresectable or metastatic BRAFV600-mutated melanoma: an ongoing multi-centric, multi-national, prospective, longitudinal, non-interventional study - BERING-Melanoma",

author = "D Schadendorf and E Richtig and C Loquai and A Forschner and R Gutzmer and S Haferkamp and J Utikal and JC Hassel and F Meier and Dirk Debus and M Fluck and D Goeppner and H Kehrer and R Dummer and \{von Moos\}, R and J Thompson and L Gengenbacher and O Michielin and C Hoeller",

year = "2022",

language = "English",

volume = "45",

pages = "236--236",

journal = "Oncology Research and Treatment",

issn = "2296-5270",

publisher = "Karger ",

number = "SUPPL 3",

}

Schadendorf, D, Richtig, E, Loquai, C, Forschner, A, Gutzmer, R, Haferkamp, S, Utikal, J, Hassel, JC, Meier, F, Debus, D, Fluck, M, Goeppner, D, Kehrer, H, Dummer, R, von Moos, R, Thompson, J, Gengenbacher, L, Michielin, O & Hoeller, C 2022, 'Encorafenib plus binimetinib in patients with locally advanced, unresectable or metastatic BRAFV600-mutated melanoma: an ongoing multi-centric, multi-national, prospective, longitudinal, non-interventional study - BERING-Melanoma', Oncology Research and Treatment, vol. 45, no. SUPPL 3, pp. 236-236.

Encorafenib plus binimetinib in patients with locally advanced, unresectable or metastatic BRAFV600-mutated melanoma: an ongoing multi-centric, multi-national, prospective, longitudinal, non-interventional study - BERING-Melanoma. / Schadendorf, D; Richtig, E; Loquai, C et al.
In: Oncology Research and Treatment, Vol. 45, No. SUPPL 3, 2022, p. 236-236.

Research output: Contribution to journal › Abstract (Journal) › peer-review

TY - JOUR

T1 - Encorafenib plus binimetinib in patients with locally advanced, unresectable or metastatic BRAFV600-mutated melanoma: an ongoing multi-centric, multi-national, prospective, longitudinal, non-interventional study - BERING-Melanoma

AU - Schadendorf, D

AU - Richtig, E

AU - Loquai, C

AU - Forschner, A

AU - Gutzmer, R

AU - Haferkamp, S

AU - Utikal, J

AU - Hassel, JC

AU - Meier, F

AU - Debus, Dirk

AU - Fluck, M

AU - Goeppner, D

AU - Kehrer, H

AU - Dummer, R

AU - von Moos, R

AU - Thompson, J

AU - Gengenbacher, L

AU - Michielin, O

AU - Hoeller, C

PY - 2022

Y1 - 2022

M3 - Abstract (Journal)

SN - 2296-5270

VL - 45

SP - 236

EP - 236

JO - Oncology Research and Treatment

JF - Oncology Research and Treatment

IS - SUPPL 3

ER -